Antibiotic treatment for children with UTI not associated with reduced risk of recurrenceJuly 11, 2007The use of prophylactic antibiotics, which involves daily administration of antibiotics to children after an initial urinary tract infection, is not associated with reduced risk of recurrent urinary tract infections, but is associated with an increased risk of resistant infections, according to a study in the July 11 issue of JAMA. Estimates of cumulative incidence of UTI in children younger than 6 years (3 percent - 7 percent in girls, 1 percent - 2 percent in boys) suggest that 70,000 to 180,000 of the annual U.S. birth cohort will have experienced a UTI by age 6, according to background information in the article. Practice guidelines for after the first UTI in children recommend an imaging study to evaluate for the presence and degree (grade) of vesicoureteral reflux (VUR; a backflow of urine from the bladder into the ureter), a condition present in approximately 30 percent to 40 percent of children with UTI. If the child has VUR, daily antibiotic (destroying or suppressing the growth of microorganisms) treatment is recommended in an attempt to prevent recurrent UTIs. Evidence is limited regarding risk factors for recurrent urinary tract infection (UTI) and the risks and benefits of antibiotic treatment. Patrick H. Conway, M.D., M.Sc., of the University of Pennsylvania Robert Wood Johnson Clinical Scholars Program, Philadelphia, and colleagues conducted a study to identify risk factors for recurrent UTI and estimate the effectiveness and possibility of resistance of antimicrobials in preventing recurrent UTI. Patients in the study were from a Children's Hospital of Philadelphia supported network of 27 primary care pediatric practices in urban, suburban, and semi-rural areas spanning three states, with children ages birth through 6 years, who were diagnosed with first UTI between July 2001 and May 2006. Among 74,974 children in the network, 611 had a first UTI and 83 had a recurrent UTI. The researchers found that factors associated with increased risk of recurrent UTI were white race (nearly twice the risk), age 3 to 4 years (2.75 times the risk), age 4 to 5 years (2.5 times the risk), and grade 4 to 5 VUR (4.4 times the risk). Severity of VUR is measured by a grade of 1-5, with 5 being the most severe. Sex, grade 1 to 3 VUR, and other antibiotic exposure had no effect on risk of recurrent UTI. Exposure to prophylactic antibiotics significantly increased the likelihood of resistant infections (7.5 times increased risk). "Given - previous findings and the unfavorable risk/benefit ratio demonstrated by the current study, we think it is prudent for clinicians to discuss the risks and unclear benefits of prophylaxis with families as they make family-centered decisions about whether to start prophylactic [antibiotics] or to closely monitor a child without prescribing [antibiotic] prophylaxis after a first UTI," the authors write. JAMA and Archives Journals |
|||||||||||||||||||||
| Related Antibiotics Current Events and Antibiotics News Articles New study finds MRSA on the rise in hospital outpatients The community-associated strain of the deadly superbug MRSA-an infection-causing bacteria resistant to most common antibiotics-poses a far greater health threat than previously known and is making its way into hospitals, according to a study in the December issue of Emerging Infectious Diseases. A Second Skin Despite advances in treatment regimens and the best efforts of nurses and doctors, about 70% of all people with severe burns die from related infections. Study reveals why certain drug combinations backfire Combination drug therapy has become a staple for treating many infections. For instance, doctors treat extensively drug resistant forms of tuberculosis with one drug that breaks down the pathogen's protective barriers and opens the door for another to deliver the deathblow. New imagining technique could lead to better antibiotics and cancer drugs A recently devised method of imaging the chemical communication and warfare between microorganisms could lead to new antibiotics, antifungal, antiviral and anti-cancer drugs, said a Texas AgriLife Research scientist. UCLA researchers reconstitute enzyme that synthesizes cholesterol drug lovastatin Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have for the first time successfully reconstituted in the laboratory the enzyme responsible for producing the blockbuster cholesterol-lowering drug lovastatin. Progress made on group B streptococcus vaccine Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus (GBS) infection is possible. Henry Ford Hospital study: A MRSA strain linked to high death rates A strain of MRSA that causes bloodstream infections is five times more lethal than other strains and has shown to have some resistance to the potent antibiotic drug vancomycin used to treat MRSA, according to a Henry Ford Hospital study. Bacteria 'launch a shield' to resist attack Researchers from the University of Copenhagen and the Technical University of Denmark along with other collaborators in Denmark and the US found that the bacterium Pseudomonas aeruginosa can 'switch on' production of molecules that kill white blood cells - preventing the bacteria being eliminated by the body's immune system. Pumpkin skin may scare away germs The skin of that pumpkin you carve into a Jack-o'-Lantern to scare away ghosts and goblins on Halloween contains a substance that could put a scare into microbes that cause millions of cases of yeast infections in adults and infants each year. Deadly stomach infection rising in community settings, Mayo Clinic study finds Mayo Clinic researchers have found that a sometimes deadly stomach bug, Clostridium difficile is on the rise in outpatient settings. More Antibiotics Current Events and Antibiotics News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||